Gefitinib (ZD1839)

Name: Gefitinib (ZD1839)
Brand: Selleck Chemicals
SKU: S1025
Rating: 5 (538 reviews)

For research use only.

Catalog No.S1025 Synonyms: Iressa

538 publications

CAS No. 184475-35-2

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Selleck's Gefitinib (ZD1839) has been cited by 538 publications

Nature, 2021, 595(7869):730-734

PubMed: 34290403 ( click the link to review the publication )

Nat Cell Biol, 2021, 23(4):377-390

PubMed: 33795873 ( click the link to review the publication )

Cell Stem Cell, 2020, 7;26(5):782-792e7

PubMed: 32348727 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(9):748

PubMed: 30135560 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00736-X

PubMed: 34562372 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2624

PubMed: 33976143 ( click the link to review the publication )
Nat Commun, 2021, 12(1):5919

PubMed: 34635651 ( click the link to review the publication )

Clin Cancer Res, 2021, clincanres.0714.2021

PubMed: 34168046 ( click the link to review the publication )

Theranostics, 2021, 11(2):824-840

PubMed: 33391507 ( click the link to review the publication )

Theranostics, 2021, 11(6):2594-2611

PubMed: 33456562 ( click the link to review the publication )

Cancer Res, 2021, canres.1153.2021

PubMed: 34301758 ( click the link to review the publication )

Cancer Res, 2021, canres.CAN-21-2426-E.2021

PubMed: 34548332 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):258

PubMed: 34404439 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E272

PubMed: 33450879 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1198

PubMed: 33801941 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009221

PubMed: 33471869 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3635

PubMed: 34298852 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3586

PubMed: 34298802 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):83

PubMed: 33446634 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):561

PubMed: 34059647 ( click the link to review the publication )

Br J Cancer, 2021, 10.1038/s41416-021-01340-x

PubMed: 34088989 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Arch Toxicol, 2021, 10.1007/s00204-021-03147-4

PubMed: 34455456 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13046

PubMed: 34165921 ( click the link to review the publication )

J Cancer, 2021, 12(18):5562-5572

PubMed: 34405017 ( click the link to review the publication )

Pharmacol Res, 2021, 170:105701

PubMed: 34087353 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(4):1873-1888

PubMed: 34012799 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(3):1277-1291

PubMed: 33889509 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1963-1974

PubMed: 33544933 ( click the link to review the publication )
Oncogenesis, 2021, 10(7):56

PubMed: 34315851 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(6):119016

PubMed: 33744274 ( click the link to review the publication )

Front Oncol, 2021, 11:665045

PubMed: 34168988 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(10)5306

PubMed: 34069970 ( click the link to review the publication )

Sci Rep, 2021, 11(1):9161

PubMed: 33911106 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Ann Transl Med, 2021, 9(14):1150

PubMed: 34430591 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Proteomics, 2021, 10.1002/pmic.202000251

PubMed: 34151541 ( click the link to review the publication )

Cancer Res Treat, 2021, 10.4143/crt.2021.385

PubMed: 33940786 ( click the link to review the publication )

Transl Oncol, 2021, 14(11):101204

PubMed: 34425505 ( click the link to review the publication )

Eur J Pharmacol, 2021, 908:174346

PubMed: 34270985 ( click the link to review the publication )

Environ Toxicol, 2021, 10.1002/tox.23125

PubMed: 33734566 ( click the link to review the publication )

Thorac Cancer, 2021, 10.1111/1759-7714.14141

PubMed: 34510760 ( click the link to review the publication )

Mol Cell Biochem, 2021, 476(10):3563-3575

PubMed: 34018148 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00582-4

PubMed: 34370268 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(1):128-142

PubMed: 33569299 ( click the link to review the publication )

Sci Total Environ, 2021, 775:145814

PubMed: 33621883 ( click the link to review the publication )

Pharmaceutics, 2021, 13(5)630

PubMed: 33925114 ( click the link to review the publication )

FASEB J, 2021, 35(3):e21393

PubMed: 33570794 ( click the link to review the publication )

Toxicol Lett, 2021, S0378-4274(21)00043-6

PubMed: 33571620 ( click the link to review the publication )
Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Nat Commun, 2020, 21;11(1):1923

PubMed: 32317663 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 6(11):eaax2271

PubMed: 32195335 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.3555.2020

PubMed: 33355298 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Aging Cell, 2020, 22:e13145

PubMed: 32323422 ( click the link to review the publication )

Elife, 2020, 9e60541

PubMed: 32940599 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01465-y

PubMed: 32978523 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3761

PubMed: 33327495 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )
Cell Death Dis, 2020, 11(9):768

PubMed: 32943616 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Front Immunol, 2020, 10:3135

PubMed: 32082304 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371577 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 31 pii: mcp

PubMed: 32234966 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 6;11(13):3762-3770

PubMed: 32328181 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1652-1662

PubMed: 32133706 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4251-4265

PubMed: 33414998 ( click the link to review the publication )

Oncogenesis, 2020, 9(10):87

PubMed: 33012785 ( click the link to review the publication )

Biomolecules, 2020, 10(1)

PubMed: 31947839 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Mol Cancer Res, 2020, 25

PubMed: 32098826 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:554704

PubMed: 33330026 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5578-5592

PubMed: 32248643 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5811-5816

PubMed: 32281297 ( click the link to review the publication )
Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7770

PubMed: 33092268 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Invest New Drugs, 2020, 38(4):1003-1011

PubMed: 31612426 ( click the link to review the publication )

Am J Transl Res, 2020, 12(11):7377-7385

PubMed: 33312374 ( click the link to review the publication )

Infect Immun, 2020, 88(4)e00819-19

PubMed: 31964750 ( click the link to review the publication )

Oncol Rep, 2020, 45(2):459-468

PubMed: 33416163 ( click the link to review the publication )

Eur J Pharmacol, 2020, 5;874:172961

PubMed: 32044322 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Thorac Cancer, 2020, 5

PubMed: 32368855 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13533

PubMed: 32558328 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13670

PubMed: 32956565 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Thorac Dis, 2020, 12(3):712-723

PubMed: 32274137 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020,

PubMed: 32843430 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):670

PubMed: 32820157 ( click the link to review the publication )

Fundam Clin Pharmacol, 2020, 10.1111/fcp.12641

PubMed: 33336420 ( click the link to review the publication )

Front Oncol, 2020, 10:603883

PubMed: 33585221 ( click the link to review the publication )
BMC Cancer, 2020, 20(1):1189

PubMed: 33276757 ( click the link to review the publication )

Exp Mol Med, 2020, 10.1038/s12276-020-0474-1

PubMed: 32728068 ( click the link to review the publication )

Cells, 2020, 9(8):E1830

PubMed: 32756527 ( click the link to review the publication )

Cytometry A, 2020, 97(1):70-77

PubMed: 31411813 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Fundam Clin Pharmacol, 2020, 10.1111/fcp.12641

PubMed: 33336420 ( click the link to review the publication )

Cell Rep, 2020, 32(5):107994

PubMed: 32755586 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Exp Cell Res, 2020, 390(2):111950

PubMed: 32188578 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Cancer Treat Res Commun, 2020, 25:100229

PubMed: 33152554 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )
Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Mol Cancer, 2019,

PubMed: 31747941 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(14):2464-2481

PubMed: 30532069 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cells, 2019, 8(12)E1495

PubMed: 31771093 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )

Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Cell Prolif, 2019,

PubMed: 31094020 ( click the link to review the publication )
Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Biomolecules, 2019, 9(10)E638

PubMed: 31652643 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Mol Carcinog, 2019,

PubMed: 30811684 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )
Mediators Inflamm, 2019,

PubMed: 32082070 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

J Cancer Prev, 2019, 24(4):217-223

PubMed: 31950021 ( click the link to review the publication )

Mol Med Rep, 2019,

PubMed: 31638204 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Clin Respir J, 2019, 13(1):23-33

PubMed: 30480362 ( click the link to review the publication )

Exp Ther Med, 2019, 18(5):3793-3800

PubMed: 31611933 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30975694 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2019, 22(5):255-263

PubMed: 31109434 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )
Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

EMBO Rep, 2018,

PubMed: 29335246 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Oncogene, 2018, 37(9):1251-1262

PubMed: 29242605 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 3;37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Basic Res Cardiol, 2018, 113(2):12

PubMed: 29349588 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )
Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018,

PubMed: 29961070 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):883-895

PubMed: 29633504 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):1775-1786

PubMed: 29624806 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

J Cell Sci, 2018,

PubMed: 29487179 ( click the link to review the publication )

Antiviral Res, 2018, 150:20-29

PubMed: 29224735 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )
Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Gen Virol, 2018,

PubMed: 29624161 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1311-1320

PubMed: 29907991 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Cell Mol Biol (Noisy-le-grand), 2018, 64(4):6-10

PubMed: 29631678 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )
Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Neuro-oncology, 2017,

PubMed: 28575494 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Elife, 2017, 6e26733

PubMed: 28737489 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(8):1102-1111

PubMed: 27524413 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Oncogene, 2017, 36(6):731-745

PubMed: 27477696 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

ACS Infect Dis, 2017, 3(8):564-574

PubMed: 28537707 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28684780 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28939861 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2017, 313(3):L477-L490

PubMed: 28522562 ( click the link to review the publication )
Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017,

PubMed: 28927099 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(40):69185-69197

PubMed: 28978189 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22325-22343

PubMed: 28423611 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92240-92253

PubMed: 29190911 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28427242 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )
Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26640141 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Sci Rep, 2016, 6:32258

PubMed: 27558531 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )
PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Anal Biochem, 2016,

PubMed: 27059751 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34395-419

PubMed: 27284014 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59809-59819

PubMed: 27494858 ( click the link to review the publication )

Oncotarget, 2016, 7(52):86134-86147

PubMed: 27863385 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(31):50258-50276

PubMed: 27384680 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27959-74

PubMed: 27058897 ( click the link to review the publication )

Tumour Biol, 2016,

PubMed: 26286833 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27556697 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

EMBO Rep, 2015,

PubMed: 26341626 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )
Int J Cancer, 2015, 137(12):2947-58

PubMed: 26089022 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25746002 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Cell Death Dis, 2015,

PubMed: 26469972 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26268703 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26639561 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 154(2):225-37

PubMed: 26487496 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144368

PubMed: 26656173 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )
Mol Med Rep, 2015,

PubMed: 25483995 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23857-73

PubMed: 26160843 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26378037 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10146-60

PubMed: 25760142 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Mol Cancer, 2014, 13:240

PubMed: 25342548 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )
Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 16):3555-67

PubMed: 24951116 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Int J Biol Sci, 2014,

PubMed: 25013379 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Prostate, 2014, 74(5):528-36

PubMed: 24435707 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Oncol Rep, 2014, 32(5):2230-6

PubMed: 25175149 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115144

PubMed: 25502225 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Biomicrofluidics, 2014, 8(3):034104

PubMed: 24926389 ( click the link to review the publication )
Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

J BUON, 2014, 19(2):466-73

PubMed: 24965408 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277177 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):4765-78

PubMed: 24946858 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

Neuro Oncol, 2013, 15(11):1469-78

PubMed: 24101737 ( click the link to review the publication )

J Cell Biol, 2013, 201(2):279-92

PubMed: 23589494 ( click the link to review the publication )

Sci Signal, 2013, 6(279):ra45

PubMed: 23757022 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )
PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62852

PubMed: 23696788 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Lipids Health Dis, 2013, 12:101

PubMed: 23849180 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 2):435-48

PubMed: 22357970 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )
Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
NCI-H1975	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJzLkS2NUDPxE1?	MmrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HT	NWLjU45iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TCVWlEPTB;MkGuOFM{OSEQvF2=	NVTXbXV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HUTU-80	M4PC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2L6XGlEPTB;MkGuOFM{PiEQvF2=	M{\IfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
PA-1	M4Thfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHNTWM2OD1{MT6yO\|g4KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HOP-62	NHrubWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXG3bIxmUUN3ME2yNU4zPzh2IN88US=>	NG\GV449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GI-1	NXHJfJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvWfZVKSzVyPUKxMlE4KM7:TR?=	NHm1cJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MC116	NGXIN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1uwc2lEPTB;MkGuNFczOyEQvF2=	M{e1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
A375	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTITWM2OD1{MT6wOVY4KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
IST-SL1	M{Luc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPsclJmUUN3ME2yNE44QDd7IN88US=>	NX\JfoRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TE-5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fsO2lEPTB;MkCuO\|Q5OiEQvF2=	NFHHUVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SiHa	NFrlZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTJyLkO3NVIh\|ryP	M13Hd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LB2518-MEL	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVH5PWNGUUN3ME2yNE4{PzN7IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BB49-HNC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjVTWM2OD1zOT65NkDPxE1?	M3zyRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HGC-27	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFOxbI9KSzVyPUKwMlE{QTRizszN	M{XQR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
Becker	NEDid2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\STWM2OD1zOT64OVQ4KM7:TR?=	M2K3RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
TYK-nu	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\wTWM2OD1zOT64N\|c5KM7:TR?=	MkO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H650	M3jPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moq2TWM2OD1zOT63OVA5KM7:TR?=	NXr0VGdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
WM-115	M4HOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn71TWM2OD1zOT62O\|c1KM7:TR?=	M1TqelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HuH-7	Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjCRohKSzVyPUG5Mlc1OjFizszN	NU\YU4I{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-N87	Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTXTWM2OD1zOT61PVkzKM7:TR?=	NHfjO2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1048	M2[1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXPTWM2OD1zOT6yN\|I3KM7:TR?=	Mnz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H446	M1\pWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFv3NWRKSzVyPUG5MlM2QDlizszN	MnKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1437	NWnxbGZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjuTWM2OD1zOT6wOFY4KM7:TR?=	MljDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
D-263MG	MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYGxT\|J{UUN3ME2xPU4xOTd{IN88US=>	NF;hUIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MFH-ino	MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETCTldKSzVyPUG4Mlk3PjlizszN	NGDoU3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
U-266	M{DySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2r5SGlEPTB;MUiuPFY1QSEQvF2=	NWLOc\|VHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OVCAR-8	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnxe\|BKSzVyPUG4MlkzPzZizszN	M4XQOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KNS-42	NHu2XVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTF6LkiwNVUh\|ryP	M3zjU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
U251	NYfuOIZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;0b2lEPTB;MUiuO\|M1PyEQvF2=	NGjEUm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MFE-280	NYiyZnI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrrPHpKSzVyPUG4MlczQTNizszN	Mlz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1563	NU\BRldKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfoOZJ[UUN3ME2xPE44OTJ2IN88US=>	MlvsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MDA-MB-361	NGfDdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjxVVZKSzVyPUG4MlU2QDhizszN	M1TqS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HLE	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTF6LkOxOFgh\|ryP	NIKy[FQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW982	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTF6LkSwO\|Uh\|ryP	M2fsVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KM-H2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDDdm5KSzVyPUG3Mlk1OTFizszN	NFv3Z2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
D-502MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HwUmlEPTB;MUeuPVgxQCEQvF2=	MnzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ES8	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPJTWM2OD1zNz64OVk{KM7:TR?=	M3jmRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SF268	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPVcndJUUN3ME2xO{43QTZ7IN88US=>	MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Calu-6	NFG0eFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fS[mlEPTB;MUeuOlc5OiEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW1783	NWfscXRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;uSnRKSzVyPUG3MlY1OTVizszN	M3;j[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H747	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf3b5JKSzVyPUG3MlUzQTdizszN	NHLNSGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1573	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTF5LkK4NlYh\|ryP	M1jQclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1581	M3LIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPjOJhKSzVyPUG3MlQ1OTFizszN	NHHJR3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RKO	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTF5LkC3OFgh\|ryP	MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MZ2-MEL	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTRTWM2OD1zNz6xN\|Mh\|ryP	NXTZ[5FQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
GI-ME-N	NEi0PFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYP0dohLUUN3ME2xOk46ODN{IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LB373-MEL-D	NVy5VoZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LzcWlEPTB;MU[uO\|I{OiEQvF2=	M3TjNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MEL-HO	Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTF4Lki4OVQh\|ryP	NF36bVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BEN	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jVNWlEPTB;MU[uOVE2PSEQvF2=	M3jmWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
M059J	NVW3THF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLJZXpKSzVyPUG2MlI5PCEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
D-283MED	NWCwZnBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYezfWdiUUN3ME2xOk41OjB7IN88US=>	NHfJbI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GP5d	MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1n1NWlEPTB;MU[uNlE5PyEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BHT-101	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2K3NWlEPTB;MU[uNlQ{QSEQvF2=	NF\lVVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HT55	NY\2dFY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHtXJd[UUN3ME2xOU46PDd6IN88US=>	NEDJcG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
no-11	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3XTWM2OD1zNT65OlY{KM7:TR?=	NE[3fpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MPP-89	NUPyRW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfJcos{UUN3ME2xOU46PDF5IN88US=>	NF62dmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HuCCT1	M4jRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETPR5VKSzVyPUG1Mlg4PCEQvF2=	MorSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H23	NX\FTXFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2roe2lEPTB;MUWuPFQ{QCEQvF2=	NFrkfXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
UMC-11	M3[3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXETmNKSzVyPUG1Mlc2OjNizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MCF7	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LZd2lEPTB;MUWuPFE1PSEQvF2=	M1z5WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
COLO-320-HSR	M4T6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTVUlN[UUN3ME2xOU42OzB5IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CW-2	M1WyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;ZTWM2OD1zNT6xOFIyKM7:TR?=	Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MOLT-4	NIPk[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jD[2lEPTB;MUWuNFQ6PyEQvF2=	NV3N[2JwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1755	NVvxT2JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HYWWlEPTB;MUSuPVk2OyEQvF2=	MoLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MIA-PaCa-2	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTF2Lkm2PUDPxE1?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TGBC1TKB	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoK2TWM2OD1zND62OlE2KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H630	NX;y[HZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnj4TWM2OD1zND65OFY4KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LAN-6	M1LwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moi1TWM2OD1zND6yOVMh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A549	M1vLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXu1XWFiUUN3ME2xOE41PzF{IN88US=>	NEH6W\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RD	NWDpNnp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHlVIxHUUN3ME2xOE41QDF\|IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KALS-1	M4HUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTF\|Lki1NlUh\|ryP	MmPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LOXIMVI	NVzrTmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDMWlNKSzVyPUGzMlYyPTFizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SK-PN-DW	NGXkUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrnXJdKSzVyPUGzMlg1OjdizszN	M1\H[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SN12C	M3nOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7F[ll6UUN3ME2xN{4{QDB6IN88US=>	NIjyWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1993	M3PJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2mxWWlEPTB;MUOuOFI5PSEQvF2=	NHfKfmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
G-361	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTF{LkmxNlkh\|ryP	NGLwXow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RH-18	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTF\|LkK5OlIh\|ryP	NFrjbHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GT3TKB	M2LEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzKTW9SUUN3ME2xNk43OzJ5IN88US=>	NUGwc\|dQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
DMS-273	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYT3dXhoUUN3ME2xNk45PjN\|IN88US=>	MlfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
C3A	NWrheolJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnzT21KSzVyPUGyMlU4QDVizszN	NIP1VWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Daoy	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTF{LkS1OFIh\|ryP	Ml23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ABC-1	NGPtPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWq3NYNLUUN3ME2xNk4{PDFizszN	MojBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KS-1	NEHXZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFv2TVNKSzVyPUGyMlI5OzJizszN	M3e4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
JAR	NWPsUo15T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTF{LkOzOlkh\|ryP	NVLPfGVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CAMA-1	NHz0THRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3mbFZKSzVyPUGyMlE3OzNizszN	M{\LdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
U-118-MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITrUHRKSzVyPUGyMlI1PDFizszN	M3mzU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
OE19	M2Hk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoK2TWM2OD1zMT65N\|Y4KM7:TR?=	M4K3U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
Mo-T	M2TTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LtfWlEPTB;MUGuPVU1OSEQvF2=	M{\MSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SCC-9	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnn[FZJUUN3ME2xNU45OTVzIN88US=>	M2nibFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HOS	NULBdo4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFn5em1KSzVyPUGxMlg3QDNizszN	Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
UM-UC-3	MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHReHBKSzVyPUGxMlc1OjFizszN	NE\GOpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MMAC-SF	M1\SV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTvTWM2OD1zMT63NlUzKM7:TR?=	NGDMc409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MLMA	M2D1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nRb2lEPTB;MUGuOlk6PyEQvF2=	M1rpbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RPMI-7951	M4TRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTFzLk[zOFgh\|ryP	M1GwWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1299	NVrtU\|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3PbVZKSzVyPUGxMlY3PDdizszN	NHPuSXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LS-411N	Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTFzLk[xNFEh\|ryP	MlK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HCC1954	NGrrVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFzLkSzOkDPxE1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
GOTO	NITmbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7qTWM2OD1zMT61NlA3KM7:TR?=	Ml\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
FTC-133	M2SzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPCTHhKSzVyPUGxMlMxQDFizszN	NYLCO4hzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LB831-BLC	M3XvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;zTWM2OD1zMT6yOVU3KM7:TR?=	NEftXYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC38	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHXTWM2OD1zMD65O\|E3KM7:TR?=	NXz5bVFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SF-295	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFyLkm5NFIh\|ryP	NHjoS4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
K-562	MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWX5WoRIUUN3ME2xNE45Ozl3IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW900	Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTFyLkiyNlgh\|ryP	M3X6b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
D-336MG	M3Pz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTFyLkewNFUh\|ryP	NELtbog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LXF-289	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nPOWlEPTB;MUCuO\|k3PyEQvF2=	M3;qTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SW962	M1TW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT3b21mUUN3ME2xNE43OjB2IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
VMRC-RCZ	NEeyToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rIWmlEPTB;MUCuOlc1QSEQvF2=	Mn3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HEC-1	NUPvUIJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\mUGlEPTB;MUCuOFA5OSEQvF2=	M4fmUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
A2058	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkK5TWM2OD1zMD61OFkyKM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
K5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFyLkOzPVUh\|ryP	M{jPbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
U031	NVzW[olLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PWTGlEPTB;MUCuNlY5PiEQvF2=	NETFcXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
YH-13	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkX3TWM2OD1zMD6zNFU4KM7:TR?=	NULMdYN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SK-UT-1	M1\wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE[3b5ZKSzVyPUGwMlI2PzRizszN	NXnzXZA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H810	NFf0S5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PYdGlEPTB;MUCuNVU6PyEQvF2=	M1;pbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DJM-1	NWf4eWlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEK1Um9KSzVyPUGwMlE4OzJizszN	MkW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAL-51	M3rmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XqUmlEPTB;MUCuNFg4PyEQvF2=	NULaNYx5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCE-4	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjKTWM2OD1zMD6xNVIzKM7:TR?=	NYL5VnNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H2342	M4X0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVS5fmJXUUN3ME2xNE4xOTV3IN88US=>	NHrvbpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A204	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFj5R3VKSzVyPUGwMlA1PjZizszN	NHP6SnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1355	M4HzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnu1TWM2OD17Lkm0NFg5KM7:TR?=	MnXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW837	M1z4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTlwOES4NkDPxE1?	M2OxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
OCI-AML2	NH\CTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PtcWlEPTB;OT64Olk3KM7:TR?=	M3\yTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EFO-21	M2jqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYmyPGFJUUN3ME25MlU5PzN3IN88US=>	M2PQeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
C32	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f2emlEPTB;OT62N\|M1KM7:TR?=	M3\LVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KP-4	NFHjbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzoTWM2OD17LkS4PFM5KM7:TR?=	MmTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
A101D	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvZSZZKSzVyPUmuOVE4OTlizszN	MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
IA-LM	NV;6O29UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTlwNEG5OlYh\|ryP	NXGxeI5zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HPAF-II	NYn0WIRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDsS3ZKSzVyPUmuNlI2OThizszN	M{\pZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
Capan-2	MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHnT3BjUUN3ME25MlQxOTB7IN88US=>	M3nCc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BFTC-909	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HhcWlEPTB;OT6xPFI6PyEQvF2=	NHn6cGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RPMI-8226	MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDGc2J7UUN3ME25MlEyOzB2IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ChaGo-K-1	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fpZmlEPTB;OT6xNFU4QSEQvF2=	NXzRS4MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H2228	MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULVfHpVUUN3ME25MlEyODhzIN88US=>	NVfHV4JGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H226	M1rYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTlwMEmg{txO	MlftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
D-566MG	M1Hq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4C4OmlEPTB;OT6wNVgyKM7:TR?=	NHXnV2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LS-1034	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDySWNKSzVyPUiuPVQ3PTJizszN	MojWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1792	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRThwOEi5NFMh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
COLO-792	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvIV2I1UUN3ME24Mlc1QTR4IN88US=>	NFP0SHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A673	Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfWeFh{UUN3ME24MlY4PjFzIN88US=>	M4XnTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
D-392MG	M3rCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRThwNk[yNVQh\|ryP	NWD5O\|dyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EGI-1	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXTTnFKSzVyPUiuOlAxQDhizszN	NVWw[GQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TGBC11TKB	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jlSmlEPTB;OD60OlE3PCEQvF2=	NGTmWpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
5637	M4XjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfQZZZKSzVyPUiuN\|ExPTVizszN	NWG0XWFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KYSE-70	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13KW2lEPTB;OD6xPVc3OSEQvF2=	NXnRPFlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
VM-CUB-1	NInZb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXNdFhKSzVyPUiuNVcxOjlizszN	NHvxbmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
AM-38	M1vsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFuzVIdKSzVyPUiuNVYzQCEQvF2=	NGnwUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H661	NHHJUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo[4TWM2OD16LkC1PFY4KM7:TR?=	Ml3xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SHP-77	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rpR2lEPTB;Nz64OlY2OyEQvF2=	MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DK-MG	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInxeFJKSzVyPUeuPFMzODFizszN	M3P6UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NB13	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTdwOEK2Olch\|ryP	M{LvZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
COLO-829	NHjDTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPmXpI6UUN3ME23MlY3PDZ\|IN88US=>	M2fsVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
OS-RC-2	MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jCNmlEPTB;Nz60PVg6PCEQvF2=	M2HYfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HCC1419	M4nOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml2wTWM2OD15LkS2PFM{KM7:TR?=	NUPmO\|hXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SKG-IIIa	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzOTWM2OD15LkS1N\|gyKM7:TR?=	Mn3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
COLO-668	NHfsRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTNZ4VZUUN3ME23MlQ{QTZ5IN88US=>	M1XkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-62	NYCzUVJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTIflFKSzVyPUeuN\|k5PjZizszN	MmT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HEL	M{PaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTdwM{e1NlEh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H2030	NHe0SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\ZZolbUUN3ME23MlM{Pjl6IN88US=>	NXjJZ5lJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
DMS-114	M3;PRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXz6Z2FmUUN3ME23MlI6PjNzIN88US=>	NYjGVldwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NOS-1	NGPLcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjjTWM2OD15LkK1PFI5KM7:TR?=	NYfWU5JYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KP-N-YS	NVH2O3dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTdwMUixOEDPxE1?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OVCAR-4	NFrnSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfiellvUUN3ME23MlE2OzVizszN	MoSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H2405	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDoTWM2OD15LkC4N\|k{KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TE-11	NFv3eXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInuWWRKSzVyPUeuNFQ6PjdizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KLE	NY\Jb2pNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;xTWM2OD14Lkm2OVE3KM7:TR?=	Mo\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
A388	NUXNVFlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;2SXRKSzVyPU[uPFk2OiEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NB12	NXf6[JV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTaUnlKSzVyPU[uO\|g1ODRizszN	MoHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
PFSK-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jSTWlEPTB;Nj63N\|Q4QCEQvF2=	NELpeIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-HEP-1	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTZwN{G3OVMh\|ryP	Ml72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Calu-3	M3v1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTkSWxZUUN3ME22MlY2PTZ6IN88US=>	NYHNN2tZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SH-4	NXrVbIhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTZwNUi4OFQh\|ryP	NFO0RVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GCT	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mne5TWM2OD14LkWzN\|g4KM7:TR?=	M2C3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MSTO-221H	M3\IR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\zOoNuUUN3ME22MlUyOTdizszN	NIfENJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GAMG	M2i0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrW[3FKSzVyPU[uOVA3OiEQvF2=	NGDDbYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CAL-120	NEjyR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\5TWM2OD14LkS1NVYzKM7:TR?=	M1jzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
VA-ES-BJ	NGfuO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTZwM{C0OlIh\|ryP	M2LmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-MEL-28	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHhWohzUUN3ME22MlIxQTZ5IN88US=>	NF3GeYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
8-MG-BA	NYi0SnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTZwMUmzO\|kh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
L-428	NXrpZ\|dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTZwMUiwN\|ch\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
Mewo	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3COJJKSzVyPU[uNVE1QDdizszN	NXjnRnN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RCM-1	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnqSWxKSzVyPU[uNFc4OTlizszN	NUL0R\|FJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KE-37	NYj2R5dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;VTWM2OD14LkC3NlU5KM7:TR?=	M{OyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
TE-10	M{PlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVviV5ptUUN3ME22MlA1QDN\|IN88US=>	M1zMZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HDLM-2	NH;lWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLIXIRWUUN3ME22MlAyPDh7IN88US=>	NW\3O5VXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CAKI-1	MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjiTWM2OD14LkCwPVg2KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
RT-112	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnhTWM2OD13LkmwNlQ2KM7:TR?=	NIWwNoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC2998	M{[zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XVSGlEPTB;NT63NVg4PyEQvF2=	NGL6OZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC1187	Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fhemlEPTB;NT63NVA{OiEQvF2=	Mn7nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HD-MY-Z	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\qdWdzUUN3ME21MlY5PThzIN88US=>	M1S5UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RMG-I	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTVwNkW5OFIh\|ryP	M2XWeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BFTC-905	M1uyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPpXVNtUUN3ME21MlY2QDd6IN88US=>	M4TxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SW1990	NYDQfodWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrxR2pKSzVyPUWuOlIzQDVizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW13	NVrHc5RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\oeGlEPTB;NT61N\|I3PSEQvF2=	NUj1c25bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
AGS	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInKeo5KSzVyPUWuOFk3OThizszN	NGj5ZnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ATN-1	NWPqSoRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTVwNEGxPFQh\|ryP	NECwNHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CGTH-W-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljUTWM2OD13LkO4OVg1KM7:TR?=	M17QZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NOMO-1	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[wcmlEPTB;NT6yN\|E4PiEQvF2=	Mn\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ALL-PO	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LKc2lEPTB;NT6yNlU5PyEQvF2=	NVnKclJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KP-N-YN	M3rh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{K4cWlEPTB;NT6xNlU6OSEQvF2=	NYXidJd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1838	NV;sU45KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkmzTWM2OD13LkCyNFc3KM7:TR?=	NFfEXIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-9	MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfUbWZKSzVyPUWuNFE2OjVizszN	NVe5XIlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KOSC-2	NVzKSHpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\DXGlEPTB;ND65PVk2QSEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ES1	NV3JfZFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTRwOU[wN\|Uh\|ryP	M4jsW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KNS-62	NYm2TG94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\2ZmlEPTB;ND65NFgxPyEQvF2=	MkfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KYSE-520	NXvBPGZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTRwOEiwNVgh\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
P30-OHK	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGe0eHFKSzVyPUSuPFE6OjlizszN	NIDabmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NB10	M37QWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHrNGVKSzVyPUSuOVk4QDFizszN	NFnsXYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A172	NX;ETFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUH4Ro5vUUN3ME20MlU2PTJzIN88US=>	Mmn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-OV-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXP3SFU6UUN3ME20MlQ3ODR{IN88US=>	NVX1[YVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
GR-ST	NXP6cXU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\s[2lEPTB;ND60N\|E5KM7:TR?=	MoLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HCC1937	NIi2SFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTRwM{e5PVMh\|ryP	NGPFVZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LU-139	NVfE[oFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTodXpnUUN3ME20MlM4OjR5IN88US=>	M1f5[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SNU-C2B	NFGxRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXT1UXp[UUN3ME20MlM1Pjh4IN88US=>	NET2UXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KARPAS-299	NXzFTmk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfZO4hvUUN3ME20MlMyODF\|IN88US=>	NUL5VYlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EW-11	NF\Bc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInYSHNKSzVyPUSuNVMzPjFizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HL-60	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPaTWM2OD12LkGyNlQyKM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TCCSUP	M1r1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTvOoFQUUN3ME20MlEyODVizszN	MoDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RCC10RGB	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzEbVM{UUN3ME20MlAyOjR4IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H441	M3rnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTNwOUewNVQh\|ryP	M3jhN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EW-16	MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULCWHBkUUN3ME2zMlk2PTd5IN88US=>	M2Psb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
JVM-2	MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XFd2lEPTB;Mz65OFc2OiEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NH-12	NYnDbWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTNwOUSxPFch\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
IST-MES1	NVnadohmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjuXJJKSzVyPUOuPVQxOjlizszN	NXGyXHZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H69	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVL4NGRZUUN3ME2zMlkxOTd6IN88US=>	NH;ldGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KURAMOCHI	NHqwN\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILHVIdKSzVyPUOuPFYxPTZizszN	NXH4VYx{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1155	NV3RSmwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13TfGlEPTB;Mz64OFE2QSEQvF2=	Mk\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H28	NU\se\|hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHEWW1VUUN3ME2zMlgzQTZzIN88US=>	NVvRT3lVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
ES4	M2TZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzZTWM2OD1\|LkiyNlg3KM7:TR?=	NEHaRoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fwWmlEPTB;Mz63OVQxPiEQvF2=	NFzhUpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
PANC-10-05	M4HGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojMTWM2OD1\|LkeyNFczKM7:TR?=	NWXCOGpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SK-MES-1	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfhVodKSzVyPUOuOlQ3OTRizszN	NXnXOVRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
C2BBe1	NWXJd\|ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnqwTWM2OD1\|Lk[0OFA4KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A2780	NWGyOXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPKTWM2OD1\|Lk[0NFg6KM7:TR?=	MljTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CaR-1	NGraUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHRenZmUUN3ME2zMlYyODR6IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SK-LU-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjqN2VbUUN3ME2zMlYxPjR3IN88US=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OAW-28	NFLtN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1v2bGlEPTB;Mz61PVQzPiEQvF2=	NULIb\|hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TE-1	NFy0UWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUi4ZYRTUUN3ME2zMlU6OTZ7IN88US=>	MoD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
639-V	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLvTWM2OD1\|LkW3O\|kzKM7:TR?=	MlHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
C8166	NID1fHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXO3U5pnUUN3ME2zMlQ3PTJzIN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NTERA-S-cl-D1	M4L5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\PUVc3UUN3ME2zMlQ1QTV5IN88US=>	M{j4dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
D-542MG	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHCNHVRUUN3ME2zMlQ1OjJ{IN88US=>	NHXPNm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LB771-HNC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTNwM{mxNlYh\|ryP	M1fBd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H727	M2\KVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfvd3JKSzVyPUOuN\|g2QDRizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW1463	NVy5RVV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTNwMk[xPVIh\|ryP	NXzYXIxkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1793	Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvDTnRHUUN3ME2zMlIyODl6IN88US=>	NH3UWpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HT-1376	NGXrZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTOeYhKSzVyPUOuNlA2ODZizszN	MlXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
647-V	MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnO5TWM2OD1\|LkG2NlIh\|ryP	M2\Od\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BCPAP	M{[xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;YPWlEPTB;Mz6wPFI6PSEQvF2=	NG\1SGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MN-60	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;tdnBKSzVyPUOuNFQ6PzRizszN	NFT2N5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
COLO-680N	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjlTWM2OD1\|LkCwOFk2KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DU-4475	M37yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJwOUmwOVIh\|ryP	MnixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1693	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFL2NlBKSzVyPUKuPVU5QTdizszN	NYHkXZVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HC-1	NGLEN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJwOUSwNVIh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KYSE-510	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37reGlEPTB;Mj64Olc5PiEQvF2=	NYHZUGY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OVCAR-3	NGnVTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYGxblVKUUN3ME2yMlg2PTl2IN88US=>	M1vRfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
PC-3	M1m3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfPeI17UUN3ME2yMlg{OzF5IN88US=>	MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BB65-RCC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mny3TWM2OD1{LkiwO\|E{KM7:TR?=	M17xb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
QIMR-WIL	M2S4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkj4TWM2OD1{Lke1PVUzKM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HuP-T4	M{TRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfWSFVjUUN3ME2yMlczQDF6IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
Detroit562	M1O4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[1c2pKSzVyPUKuOlk5PDVizszN	MkjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DMS-79	NF3tWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn:0TWM2OD1{Lk[5Nlg1KM7:TR?=	M1rQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MC-IXC	NIfHc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjlTWM2OD1{Lk[0OFU{KM7:TR?=	NHH2dms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-8	NWn0dWVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\Lb5hKUUN3ME2yMlY{PjV\|IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MKN7	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkL4TWM2OD1{Lk[yO\|Q5KM7:TR?=	Mk\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HH	M2jYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnFZWtDUUN3ME2yMlQ6QDV2IN88US=>	NULFNFVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CFPAC-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTJwNEO4OlQh\|ryP	NGP3fXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HTC-C3	NVzyWmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\1eGlEPTB;Mj60NlI3PyEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NY	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPTcJhKSzVyPUKuN\|czPyEQvF2=	MkO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KU812	NIrJXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmWzTWM2OD1{LkO2O\|c6KM7:TR?=	MoK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
EW-18	NFe4U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTPTWM2OD1{LkO1OFcyKM7:TR?=	NE[wdpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H2170	M4rDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPPTWM2OD1{LkO0O\|g{KM7:TR?=	NEG4b489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
JVM-3	NX3WbpJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHnVGFKSzVyPUKuN\|Q3PDNizszN	M3zVWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
IGROV-1	M{T2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorMTWM2OD1{LkOxNlM4KM7:TR?=	NHWwdG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A498	M2\OTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzOfnlKSzVyPUKuNlk1OTVizszN	M4O3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BT-20	NFjJOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTJwMk[3OFQh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SCC-4	NXniTZppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHGxcoZKSzVyPUKuNlE4PzZizszN	M3PWO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
786-0	NFzCWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PNbGlEPTB;Mj6xPFQxPiEQvF2=	NXfPZZFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RXF393	NIrZb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPkOo1KSzVyPUKuNVMxOzZizszN	MmfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KARPAS-45	M1nte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7EXI1KSzVyPUKuNVI1PzlizszN	M4LaT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RPMI-8866	NFrvbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkK3TWM2OD1{LkC4OFgyKM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H2009	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEiwcWtKSzVyPUKuNFYzOTRizszN	MoT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1116	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrMO25FUUN3ME2yMlA3ODB7IN88US=>	NYPuXJpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EKVX	MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfmTWM2OD1{LkC0PVM6KM7:TR?=	NUmzZVZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TGBC24TKB	NX35PIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULFR5BnUUN3ME2yMlAzQTZzIN88US=>	M1nyTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-12T	NXnlOpczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjnOnp4UUN3ME2yMlAyQDZzIN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC70	NHOyU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVP5SnFkUUN3ME2yMlAxQDF3IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OMC-1	NXW1d4dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7tOm12UUN3ME2xMlk6QDh6IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
EPLC-272H	NXS5fnpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTFwOEW1OFkh\|ryP	NYTGNFRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H209	M2\kUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfMT2luUUN3ME2xMlc4OjZ7IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1666	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFwN{S3NFQh\|ryP	MmqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
COLO-678	NYPEVmttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGf3XIFKSzVyPUGuO\|M1PDRizszN	NFHMeY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
PANC-03-27	M2LmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmW4TWM2OD1zLkewNVM6KM7:TR?=	MoDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BB30-HNC	NXvmOldRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PNcWlEPTB;MT62PFk4OiEQvF2=	M3[2RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
ML-2	NWjicJNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fFdWlEPTB;MT62OFAzQSEQvF2=	NXvjdph[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BT-549	NV\GeG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXPcWliUUN3ME2xMlU5PzR5IN88US=>	NEPoTFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HSC-3	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHSTWM2OD1zLkW0N\|gh\|ryP	MoPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LAMA-84	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoG4TWM2OD1zLkWzPFE2KM7:TR?=	M3nQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SCC-25	NUD4dVJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzSN5hrUUN3ME2xMlUzOzJ{IN88US=>	NVPIeIRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SAS	NGfScoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWT1Z45lUUN3ME2xMlUyPjJ{IN88US=>	Mk\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BE-13	M2HPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjnbml4UUN3ME2xMlUxPjdzIN88US=>	NXPNRWpoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
J82	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfsc3RKSzVyPUGuOFU4PjZizszN	NHXoTlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
697	NHzCZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLmVVh3UUN3ME2xMlQ1OTB2IN88US=>	M4DGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H526	M4H2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTFwNEO4NlYh\|ryP	NIXp[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RH-1	M2PqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTFwNEGxN\|Yh\|ryP	MnLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CCRF-CEM	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjPTWM2OD1zLkSxNVEh\|ryP	M{e4eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NB5	M2j4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDVTWM2OD1zLkSwPFk1KM7:TR?=	Ml7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KMOE-2	NVT1fVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XyPGlEPTB;MT6zPVgyPSEQvF2=	MknMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-N-DZ	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLYTWM2OD1zLkO2PVQ4KM7:TR?=	NXTKWlVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SW48	NVG0O3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jmXmlEPTB;MT6zOlYyQCEQvF2=	Mk\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW954	NUDJdoNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjBTWM2OD1zLkO0NFQ5KM7:TR?=	M375SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1650	M{Wxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFy2bYVKSzVyPUGuN\|M1QDJizszN	NH7LdHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NKM-1	NGHabWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLlbGJlUUN3ME2xMlMzPTl5IN88US=>	MkLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1092	M33yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPy[mFKSzVyPUGuN\|A5PSEQvF2=	NY\mcJNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CTV-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvLTWM2OD1zLkOwPEDPxE1?	MnjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
GCIY	NUC5e3NDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTFwM{CxN\|Ih\|ryP	MmLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1088	NWe3fFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLKTWM2OD1zLkK5OlA4KM7:TR?=	NIKxWok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
769-P	NV\WNXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTFwMke5NVgh\|ryP	M3;HWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
OAW-42	NV;kXXB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTFwMke4NlUh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SNU-449	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFwMkKyNFgh\|ryP	MkDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MKN1	NVLLTGNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlm3TWM2OD1zLkKxPVg4KM7:TR?=	MlzTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1648	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rKZmlEPTB;MT6xNFYyPiEQvF2=	MlP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KU-19-19	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moe3TWM2OD1zLkC4OVQyKM7:TR?=	NW\a[YliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MHH-PREB-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;OXHFQUUN3ME2xMlA5PDVzIN88US=>	NUTsZ\|VQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EM-2	NUPkR4xOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\pTWM2OD1zLkCzNFE3KM7:TR?=	MnvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1304	NGG4O5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXqTWM2OD1zLkCxOlQ{KM7:TR?=	NYTOd5g2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
DOHH-2	NGHOSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFwMECwNlEh\|ryP	NWm3S41XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MS-1	M{\Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTl7ND62PUBvVQ>?	NHPKcng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-NEP-1	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fmV2lEPTB;OUi5MlQ1KG6P	NI\Pe4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HT-3	NWXaellWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXjTXNKSzVyPUm4Nk41OSCwTR?=	NWTnO3I2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BHY	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X6O2lEPTB;OUe1MlQ5KG6P	NHr3RnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BT-474	M2ro[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPmTWM2OD17M{iuNVQhdk1?	NGrEPZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CAPAN-1	NWHHPW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETjXHZKSzVyPUi4N{4zQSCwTR?=	M2n2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H2126	M3KzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jOcGlEPTB;OEiyMlg{KG6P	M{DOTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
COR-L88	NH;mcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTh6Mj6yOkBvVQ>?	M4LKXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DEL	NETHWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTh5Nz62OUBvVQ>?	M{LMR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
AU565	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTh4OT62JI5O	M3\S[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
23132-87	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTh4ND6yPEBvVQ>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LoVo	NH;iNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX5TWM2OD16NUmuNFYhdk1?	Mk\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
TE-12	NUL5clNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlL5TWM2OD16MkGuNVEhdk1?	NWjrdGhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EC-GI-10	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[2VmlEPTB;N{i4MlUzKG6P	NGLY[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LU-135	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzyRWx{UUN3ME23PFMvODNibl2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A431	Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTXTWM2OD15OECuNFQhdk1?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TE-6	Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mom0TWM2OD15NkSuN\|Ehdk1?	NHHORYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
COLO-684	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnET4tKSzVyPUe1N{4xOSCwTR?=	M363O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HAL-01	M{TUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rlWWlEPTB;N{O0MlcyKG6P	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1770	M1fYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTd{Mj60JI5O	NFfPXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LU-134-A	NXzFepM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEP3[mJKSzVyPUexPU4xQSCwTR?=	NFzKSog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
L-363	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWG0N3R1UUN3ME22O\|EvQTRibl2=	NFjMSXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ETK-1	NF\MbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXhSGxqUUN3ME22OlIvPTlibl2=	MoD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
COR-L105	NUD3SZdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnDRXBOUUN3ME22OlIvPTNibl2=	NGXzOm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NBsusSR	M2DWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfGTnpKSzVyPU[0Ok42OiCwTR?=	NGDW[JE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ME-180	M3vkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3C[GE6UUN3ME22N\|IvQSCwTR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DBTRG-05MG	NGfJeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnQRm9KSzVyPU[zNk4zQCCwTR?=	M{Tt[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MV-4-11	M{HPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfqTWM2OD14MkeuO{BvVQ>?	NYrYS5I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrDVFVKSzVyPU[yOU4zQSCwTR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
Ramos-2G6-4C10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3kN\|NtUUN3ME22NlEvPDZibl2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NB69	NHzuXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPme2VGUUN3ME22NVQvOzVibl2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
FADU	Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTZyND62PUBvVQ>?	NYHtNHZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1623	NUfoeHZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHOxcmtKSzVyPUW5PU4{PiCwTR?=	Mlr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAL-39	NYHuS5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTV7Nj6zJI5O	NWTXNW9[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
Ca9-22	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPqTWM2OD13OEiuOlQhdk1?	M1foZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAN	NEC3RppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTV6MD63OkBvVQ>?	MmrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RS4-11	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrKTWM2OD13NkiuOVkhdk1?	NEPicIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DSH1	NH3D[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnSzTWM2OD13Nk[uPFghdk1?	MoTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NB7	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDGcFRKSzVyPUW0Ok4{OiCwTR?=	NH\IU249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H82	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLNenNKSzVyPUW0NE42KG6P	NFrQRpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KYSE-180	M2L4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3NeW5KSzVyPUWzNE43OiCwTR?=	NX62cJRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H358	NVSzSpJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXjV2o5UUN3ME21NlcvPjZibl2=	M1TPVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SCC-15	NU\CdHF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mor6TWM2OD13MkWuOlghdk1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HN	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7yUYJKSzVyPUWxO{4{QCCwTR?=	NUK1R25iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TK10	NX7ReWFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLITWM2OD13MUWuNVEhdk1?	NYq5bVc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MOLT-13	NU\DcGdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LSdmlEPTB;NUG0MlgzKG6P	NH7Zc\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-MEL-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELOR\|BKSzVyPUWxNE46QSCwTR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HO-1-N-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnKwTWM2OD13MEmuNlUhdk1?	NFzjT2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KYSE-270	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXmwOW5tUUN3ME20PVgvPjVibl2=	NWPjZYN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BPH-1	NH3ZPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfXd41KSzVyPUS5NU4yPiCwTR?=	Mlz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
EFO-27	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTR3ND63OEBvVQ>?	M{KyPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DoTc2-4510	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTR2Mj6xNkBvVQ>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CTB-1	NW\NVoYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX75Oo9yUUN3ME20NlQvPCCwTR?=	MknjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KY821	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTRyOD61O{BvVQ>?	M3XDSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NUGC-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTRyMT64NUBvVQ>?	M4S2VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MDA-MB-175-VII	M2XhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHobHpWUUN3ME2zO\|gvQDhibl2=	MkDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAL-33	M1ztNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\LTWM2OD1\|N{CuPUBvVQ>?	NV24cms2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KASUMI-1	MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HwPWlEPTB;M{[2Mlc{KG6P	NEm1[4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ECC10	NWHjNZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzTcZNKSzVyPUO1Nk46PiCwTR?=	NVnFeFNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
A4-Fuk	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXMSFhsUUN3ME2zOVAvODJibl2=	M1vwRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-MEL-24	MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrVUpFwUUN3ME2zN\|cvQDdibl2=	MkD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HCC1806	M2H3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\PemlEPTB;M{O3MlUyKG6P	MnPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
PC-14	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\3R4NKSzVyPUOzN{41OSCwTR?=	NV7lRpZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
ACHN	NVu0U\|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPMeFVKSzVyPUOzNU41KG6P	MnXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
P12-ICHIKAWA	NWXMTppST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTN{OD6wOkBvVQ>?	M2qxV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
TI-73	NIj5O\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\LUHQ3UUN3ME2zNVIvPzVibl2=	NUntcIJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CAL-54	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTNzMT6yN{BvVQ>?	MkTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SBC-1	MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL3T5ZrUUN3ME2zNFcvPzlibl2=	NE[yNpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BALL-1	NYf2cIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTJ7Nz60NkBvVQ>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CAL-27	NIPMVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJ6OT6wPEBvVQ>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-SNU-1	M3PyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUCxRVJvUUN3ME2yPFMvOzJibl2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCE-T	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGr4UHdKSzVyPUK3PU44QSCwTR?=	NEHaUJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MEG-01	M3nZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTJ5Nj63OkBvVQ>?	NWi1fZJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CAL-72	NWXKSWZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[y[opXUUN3ME2yOlgvPzNibl2=	Mn\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KYSE-450	NIDzUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zlXWlEPTB;MkS3MlkzKG6P	NV3We5drRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EW-13	NVfBcWpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHGyNVJKSzVyPUKyOU4yKG6P	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DU-145	NFi1O45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPITWM2OD1{MUmuNFQhdk1?	M{DrT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KYSE-140	M3vyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\5NmlEPTB;MkC5Mlk3KG6P	M4rZRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CHL-1	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLPTWM2OD1{MEiuOVEhdk1?	NVjCfo43RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KG-1	M2S4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfaTZdKSzVyPUKwOE4{PCCwTR?=	NYrhXIxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[wb2lEPTB;MUm0Mlk{KG6P	M4KzcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BV-173	NVvwW3l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDMTWM2OD1zOE[uOVUhdk1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LU-65	M4OxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLn[I1KSzVyPUG2Ok43OSCwTR?=	M2n3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HSC-2	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7STWM2OD1zNkWuOVchdk1?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H292	M4joUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVX0WpN6UUN3ME2xOlIvPjZibl2=	Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
H9	NH7jbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLEfHdKSzVyPUGzO{4zKG6P	NHLPPJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DOK	MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fYXGlEPTB;OUOuOlIhdk1?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HSC-4	NHzjVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHi0ZpVKSzVyPU[xMlU{KG6P	MljIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DB	MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\HNo5KSzVyPU[wMlk3KG6P	NFjrZ4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HuO-3N1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPESYJMUUN3ME21Ok4xQSCwTR?=	NVjsUnBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCC2218	NH3xO\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nHc2lEPTB;NUCuOVkhdk1?	Moi5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
EW-3	NWO4[\|FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPBTWM2OD12Nj6wOEBvVQ>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-SNU-5	MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTJ6LkG5JI5O	MmDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H720	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTJ4LkmyJI5O	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
EoL-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTVwMUegcm0>	Ml3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MIAPaCa2	NV\JU4pXSXCxcITvd4l{KEG\|c3H5	M2fweFIxKM7:TR?=	MnfVNlQhcA>?	MWTEUXNQ	NH\iNmtld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KGOjc4Dhd4UhOyCjY4TpeoF1cW:w	MmHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
MIAPaCa2	MXXBdI9xfG:\|aYOgRZN{[Xl?	NHrhS5AyOCEQvF2=	NF3vZ2YzPGhib4KgOFghcA>?	NHL1dWRFVVOR	M4fHVIRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYO=	M4DmdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
MIAPaCa2	M1PiNGN6fG:2b4jpZ{BCe3OjeR?=	NYSzVZJMOSEQvF2=	NWe0TYVYOTBiZB?=	NF3qTphFVVOR	MYfoZZMhdm9iY4n0c5RwgGmlaYT5JIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINwdG:weTDmc5Ju[XSrb36=	NXX2ZYZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
MIAPaCa2	M2\nSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOyMlUh\|ryP	MljLO\|IhcA>?	M4fiNWROW09?	MWHoZZMhdm9iZ4Lve5RpKGmwaHnibZRqd25?	NFTTVos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES2OlU2PSd-MkC0OlY2PTV:L3G+
H1975	NYXvXnVzU2mwYYPlJGF{e2G7	MXewMlUh\|ryP	NHTUZmkzPCCq	NFT4WHNFVVOR	MX\kc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	NIH6PVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzPVM1Oid-MkKzN\|k{PDJ:L3G+
H1975	MVPLbY5ie2ViQYPzZZk>	Ml3rNE42KM7:TR?=	NYS3VXFrOjRiaB?=	M1[wOmROW09?	MUHkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEW{azDwbI9{eGixconsZZRqd25?	NXvjUJE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|k{PDJpPkKyN\|M6OzR{PD;hQi=>
H1975	Mnv5T4lv[XOnIFHzd4F6	MV[wMlEzPSEQvF2=	MYeyOEBp	MV;EUXNQ	NIjxSG1ld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?	M3[zUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O5N\|QzLz5{MkOzPVM1OjxxYU6=
H1975	MWfLbY5ie2ViQYPzZZk>	MVewMlM{KM7:TR?=	M3LFbFIhcA>?	NFr5W2dFVVOR	M2LZbYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KHCqb4PwbI9zgWyjdHnvci=>	M2q0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK0PFk5Lz5{NEGyOFg6QDxxYU6=
H1975	NYL5bGliU2mwYYPlJGF{e2G7	MXywMlM{KM7:TR?=	MXKyJIg>	M1jYdGROW09?	NVqxdJZY\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?	MorBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkS4PVgoRjJ2MUK0PFk5RC:jPh?=
H1975	NXnuU\|A4U2mwYYPlJGF{e2G7	NGfjc24xNjN\|IN88US=>	Mm\iNkBp	M3\aNGROW09?	NXnJOmtN\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEGNVDDwbI9{eGixconsZZRqd25?	MmjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkS4PVgoRjJ2MUK0PFk5RC:jPh?=
HCC827	M1PRU2tqdmG\|ZTDBd5NigQ>?	MnLTNE4yOSEQvF2=	MXWxJIg>	NYHmRVVKTE2VTx?=	NV7mSlVncGG\|IH7vJIlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGVITlJiYYPz[ZN{\WRiYYOgdoVkd3[ncomgc4YhTUeIUjDheZRweGixc4Doc5J6dGG2aX;u	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NEi5PEc,OjRzMkS4PVg9N2F-
H1975	MX3GeY5kfGmxbjDBd5NigQ>?	MUixJO69VQ>?	M1XNSFI1KGh?	NYe0PW9TTE2VTx?=	MULkc4V{KG6xdDDpcohq[mm2IFXST{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0>	MkTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MEe1PVEoRjJ2NkC3OVkyRC:jPh?=
H1975	NGH2dWtMcW6jc3WgRZN{[Xl?	Mk\4NUDPxE1?	MkDsNlQhcA>?	NUPBUXh5TE2VTx?=	M3rqc4Rw\XNibn;0JIlvcGmkaYSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZyN{W5NUc,OjR4MEe1PVE9N2F-
LNCaP	M4nDUmZ2dmO2aX;uJGF{e2G7	MnLQNVAh\|ryP	NUXyVpJsOmhib4KgOEBp	NW\DcnNITE2VTx?=	NFvUV4lld2W\|IH7veEBqdmirYnn0JIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiaX3teY5weHW{aX\p[YQh\myjZz30ZYdo\WRiQn34JIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzN{UG3BWHA>	NFvyXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2O\|MyOid-MUi2Olc{OTJ:L3G+
A431	NGjo[HpMcW6jc3WgRZN{[Xl?	M3nqclEh\|ryP	NW\SPGVOOSCq	MlfaSG1UVw>?	M1H5eYhieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	M1PpV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOVk1Lz5{NEmwNFU6PDxxYU6=
NCI-H1975	MX;GeY5kfGmxbjDBd5NigQ>?	M3LZfFExKM7:TR?=	NX\yc3V1QCCq	NWq5Rot4TE2VTx?=	MmTx[I9meyCwb4SgbY5pcWKrdHmgSWdHWiCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzFzNkG2PEc,OjNzMU[xOlg9N2F-
HCC827	MYjDfZRwfG:6aXOgRZN{[Xl?	M360[FAvPSEQvF2=	NGXXUnQ4OiCq	MmP5SG1UVw>?	NHS2Onhp[XNibn:gZ5l1d3SxeHnjbZR6	M4fDPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
HCC827	MV7GeY5kfGmxbjDBd5NigQ>?	NFvIcGkxNjVizszN	NXXrNolQOiCq	NFnrRWtFVVOR	MXPkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDR2L{SyJJBpd3OyaH;yfYxifGmxbh?=	MnK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
HCC827	MWfGeY5kfGmxbjDBd5NigQ>?	M1G1b\|AvPSEQvF2=	M3zTUlIhcA>?	MlvWSG1UVw>?	MUDkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdg>?	M4rTfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
SW620	M{TVfmN6fG:2b4jpZ{BCe3OjeR?=		MoW0OFghcA>?	NEjCWodFVVOR	NX3EVHhSUUN3ME2yPE4zKM7:TR?=	M3LyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOVk1Lz5{NEmwNFU6PDxxYU6=
Sf9	Mn3nT4lv[XOnIFHzd4F6		MknZNVAhdWmw	M1fFeGROW09?	MmPoTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJJJm[2:vYnnuZY51KGircz30ZYdo\WRiRVfGVkAp[W2rbn:gZYNq\CB4NEWtNVE5PiliZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd\|MUK4NUc,OjR5M{GyPFE9N2F-
HepG2	NFnkcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{HNR\|I1KGh?	MkfLSG1UVw>?	MojXTWM2OD14LkSyJO69VQ>?	NIX6WIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEezNVI5OSd-MkS3N\|EzQDF:L3G+
Hela	M13DN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH3H[4gzPCCq	MnOwSG1UVw>?	M{PXXGlEPTB;Mj62O{DPxE1?	MlnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5M{GyPFEoRjJ2N{OxNlgyRC:jPh?=
NCI-H1975	MX3GeY5kfGmxbjDBd5NigQ>?	MUexNFAh\|ryP	MlvhNVUxKG2rbh?=	MmjBSG1UVw>?	M1HHVmlv\HWldHnvckBw\iCQTzDwdo9lfWO2aX;uJIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	NE\aN449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[wO\|U6OSd-MkS2NFc2QTF:L3G+
BEAS2B	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVr5N3h5PTBizszN	NVHKSFd2PzJiaB?=	MV;EUXNQ	M{ntZWlEPTB;MUOuPVQh\|ryP	NWTMWmJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NFc2QTFpPkK0OlA4PTlzPD;hQi=>
KB	MmXiT4lv[XOnIFHzd4F6	MX[xNEDPxE1?	M3\iZlEhcA>?	NEfoR5dFVVOR	MmLOTY5pcWKrdHnvckBw\iCHR1[td5RqdXWuYYTl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIFXHSnIhf2m2aDDJR\|UxKG:oIECuNFI2KM7:TR?=	MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUGxNlMoRjJ2NEGxNVI{RC:jPh?=
Calu3	MnrPR5l1d3SxeHnjJGF{e2G7		M2XaW\|czKGh?	M3\ZUWROW09?	M1XJfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNidHV\|IHPlcIx{KGW6cILld5NqdmdiSFXSNkB4cXSqIFnDOVAhd2ZiMD65PUDPxE1?	M4LJUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
A431	M2fZ[2N6fG:2b4jpZ{BCe3OjeR?=		MWW3NkBp	NWWyXnlQTE2VTx?=	MlTwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKge4l1cCCLQ{WwJI9nKDBwNUWg{txO	M3zZZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
MDCK2	M33xU2Z2dmO2aX;uJGF{e2G7	MlTpNU45KM7:TR?=	NFvFfJI4OiCq	MYLEUXNQ	MXLJcohq[mm2aX;uJI9nKGi3bXHuJGJEWlBiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJGhw\WOqc4SgN\|M{PDJiYXPjeY12dGG2aX;uJJdqfGhiSVO1NEBw\iB\|LkG5JO69VQ>?	NWHZUm15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFQzOTNpPkK0NVg1OjF\|PD;hQi=>
MDCK	NYXDRXZMS3m2b4TvfIlkKEG\|c3H5		NFXNWYc4OiCq	NVToR20{TE2VTx?=	MnLaS2k2OD1zLkS1JO69VQ>?	NXHhOnpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFQzOTNpPkK0NVg1OjF\|PD;hQi=>
BCRP-MDCK2	NWTFcGFITnWwY4Tpc44hSXO\|YYm=	MVqxMlgh\|ryP	MXO3NkBp	M4P1WGROW09?	NGLkSIxT\WS3Y4Tpc44hd2ZicHzhd41iKG2nbXLyZY5mKGW6cILld5Nqd25ib3[gRmNTWCCneIDy[ZN{cW6pIILldI9zfGW{IHflcoUhT0[S	NFvUe5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4OFIyOyd-MkSxPFQzOTN:L3G+
BCRP-MDCK2	MmX4SpVv[3Srb36gRZN{[Xl?	MYCxMlgh\|ryP	MnvWO\|IhcA>?	NH\CdYtFVVOR	MkPHTY5kemWjc3Wgc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZR	M3LGRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUi0NlE{Lz5{NEG4OFIyOzxxYU6=
A431	NV[zWZpoU2mwYYPlJGF{e2G7	NGDvbpgyODBizszN	NUK0dFVIOzBibXnu		M2n2cmlvcGmkaYTpc44hd2ZiRVfGVkBqdiC\|aHXkJI1mdWK{YX7lJJZme2mlbHXzJJdqfGhiSVO1NEBw\iBzLkGg{txO	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NESzNkc,OjRyOUS0N\|I9N2F-
HCC827	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnMNVAh\|ryP	MUS3NkBp	M3ToeWROW09?	M1rrSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[4VncXSrbnniMZNmdnOrdHn2[UBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO\|UxKGSnbHX0bY9vKHerdHigTWM2OCCxZjCwMlAxPThzIN88US=>	M37nUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEWzOlc1Lz5{NEC1N\|Y4PDxxYU6=
HCC827	MXnGeY5kfGmxbjDBd5NigQ>?	MVSwMlUh\|ryP	MoLJNkBp	M1\aXmROW09?	MWHJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?	M3PDelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
HCC827	NFvSU2ZMcW6jc3WgRZN{[Xl?	MYGwMlUh\|ryP	NX7y[5ZSOiCq	NV3iT5pWTE2VTx?=	MkDZTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?	MmHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
A549	NVO5do96TnWwY4Tpc44hSXO\|YYm=	NU\iZVRpOSEQvF2=	MkXmNUBp	NH6yVFdFVVOR	MXLD[YxtfWyjcjD1dJRic2V?	NWjydXRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PFg{PTRpPkKzPVg5OzV2PD;hQi=>
A549	MXXLbY5ie2ViQYPzZZk>	Mn[1NUDPxE1?	NWHK[5I3OSCq	NH63SYtFVVOR	MljHTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFM6QSEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl6OEO1OEc,OjN7OEizOVQ9N2F-
HCC827	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\ze\|czKGh?		NWLmelZYUUN3ME2wMlAyOiEQvF2=	NGjMTIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m3N\|E3QCd-MkO5O\|MyPjh:L3G+
PC9	MnmyT4lv[XOnIFHzd4F6		NGnXS5AzKGh?	MWrEUXNQ	M3rDd2lvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEC4O{DPxE1?	NVTJV5pXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|A6QTRpPkKzPVMxQTl2PD;hQi=>
LoVo	MnHnT4lv[XOnIFHzd4F6		NV\5NYJwOiBiaB?=	MkLuSG1UVw>?	MUPJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB4MjFOwG0>	NX7kZ5EzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|A6QTRpPkKzPVMxQTl2PD;hQi=>
SH-SY5Y	NH7TRllEgXSxdH;4bYMhSXO\|YYm=		NXnvboM4PzJiaB?=		MUPJR\|UxRTF6LkKxJO69VQ>?	NFXzRnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3NVkxQSd-MkO4O\|E6ODl:L3G+
A549	NWfsfIZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXHUTWE5PzJiaB?=	MYPEUXNQ	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIfpcIQhfHmyZTDFS2ZTN2tvUnHzJIRmeGWwZHXueEBpfW2jbjDBOVQ6KGOnbHzzJJdqfGhiSVO1NEBw\iB2Lk[yOkDPxE1?	MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUKzNVgoRjJ\|N{myN\|E5RC:jPh?=
16HBE	MXPGeY5kfGmxbjDBd5NigQ>?	MX[xNFAh\|ryP	NIDYfG8yPTBibXnu	MXrEUXNQ	M1\BRmlv\HWldHnvckBw\iCwaYTybYMhd3irZHWgdJJw\HWldHnvckBqdiCqdX3hckAyPkiERTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFS2ZT	M13GSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myN\|E5Lz5{M{e5NlMyQDxxYU6=
16HBE	Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV:3NkBp	MXzEUXNQ	MkLURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiBzNljCSUBk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBGT0[UIIfpeIghUUN3MDDv[kAyNjZyMTFOwG0>	M1LsSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myN\|E5Lz5{M{e5NlMyQDxxYU6=
NCI-H1975	NXfUdWVKS3m2b4TvfIlkKEG\|c3H5	NUfaUWg2OTBizszN	NUHDPHUyPzJiaB?=	MYrEUXNQ	MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kA3NjlzNzFOwG0>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4OES0NUc,OjN4Nki0OFE9N2F-
16HBE14o-	NVTyO5RKS3m2b4TvfIlkKEG\|c3H5	NFW5PYEyOCEQvF2=	Mn;GO\|IhcA>?	NV71RYh2TE2VTx?=	MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>	NUXSbYd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1PDFpPkKzOlY5PDRzPD;hQi=>
Sf9	NYnQbpNDU2mwYYPlJGF{e2G7		MXWxJIg>	NIPwfplFVVOR	NELXZXFKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>	NGTzSYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNVY6OSd-MkO2NVE3QTF:L3G+
PC9	M163dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r2TFExKM7:Zz;tUC=>	Mne0O\|IhcA>?		NVPOb5hYUUN3ME2wMlAyPCEQvF2=	M125Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVY5Lz5{M{GxOlE3QDxxYU6=
HCC827	MnXBR5l1d3SxeHnjJGF{e2G7	NH7sSFQyOCEQvHevcWw>	NFzVRZI4OiCq		MVjJR\|UxRTBwMECxOUDPxE1?	NGCwR4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GxOlE3QCd-MkOxNVYyPjh:L3G+
FADU	NIjRPYxEgXSxdH;4bYMhSXO\|YYm=	M1;WVFExKM7:Zz;tUC=>	MVe3NkBp		NX:ySWg{UUN3ME2wMlA2KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzFzNkG2PEc,OjNzMU[xOlg9N2F-
Calu3	NYjoNJc6S3m2b4TvfIlkKEG\|c3H5	NUf6TXJTOTBizsznM41N	NF3VUJg4OiCq		NGDBTHdKSzVyPUGuOkDPxE1?	NVL5eoxGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNVYyPjhpPkKzNVE3OTZ6PD;hQi=>
A498	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEm4JINmdGy\|IHX4dJJme3OrbnegSWdHWiCjbnSgV3JEKHerdHigTWM2OCCxZjC4MlYh\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhzOEi0PEc,OjJ6MUi4OFg9N2F-
SGC7901	NX7MR2I5S3m2b4TvfIlkKEG\|c3H5		MmHVO\|IhcA>?		MWPJR\|UxRTFyLkK2JO69VQ>?	M2fJTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{K3OFQ6Lz5{MkeyO\|Q1QTxxYU6=
HT-29	NGLuWJFEgXSxdH;4bYMhSXO\|YYm=		Mkf5O\|IhcA>?		NY\XT3RGUUN3ME2zMlM3KM7:TR?=	M4WwdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{K3OFQ6Lz5{MkeyO\|Q1QTxxYU6=
H460	M{nWemN6fG:2b4jpZ{BCe3OjeR?=		NGjsOmM4OiCq		M4HyZWlEPTB;NT61PUDPxE1?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{N{S0PUc,OjJ5Mke0OFk9N2F-
A431	NHfUO45McW6jc3WgRZN{[Xl?	NHzZUZEyODBizszN	NXzhUW9nOzBibXnu		NHvPSnZKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ7OEe4Nkc,OjJ4OUi3PFI9N2F-
HCC827	NXLmXW5uU2mwYYPlJGF{e2G7	M4K5UFAvOTJ3IN88US=>	NYfUbGU3OjRiaB?=	NVixeohVTE2VTx?=	NGT2d\|FKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	M3nSc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O5N\|QzLz5{MkOzPVM1OjxxYU6=
HCC827	NFrQRWFMcW6jc3WgRZN{[Xl?	M4\6O\|AvOTJ3IN88US=>	M4jDeFI1KGh?	MoKzSG1UVw>?	MV\Jcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhTXKtIIDoc5NxcG:{eXzheIlwdg>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|OUO0Nkc,OjJ\|M{mzOFI9N2F-
HCC827	MlrwT4lv[XOnIFHzd4F6	MknzNE4yOjVizszN	MXqyOEBp	M2nPUGROW09?	MnGzTY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51KFlzME[4JIF2fG:yaH;zdIhwenmuYYTpc44>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|OUO0Nkc,OjJ\|M{mzOFI9N2F-
MCF7	NHX3VYtEgXSxdH;4bYMhSXO\|YYm=	M1j5OVExKM7:TR?=	MlvPOFghcA>?		M2jUR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iTVPGO{Bk\WyuczDveoVzNWW6cILld5NqdmdiRYLiRlIh[2WubIO=	MoHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzM{izNFgoRjJ{MUO4N\|A5RC:jPh?=
BT474	MoL6R5l1d3SxeHnjJGF{e2G7	MnuzNVAh\|ryP	M3fYPFQ5KGh?		M3L2[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iQmS0O\|Qh[2WubIO=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF\|OEOwPEc,OjJzM{izNFg9N2F-
MCF7	Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDzd3Z3OTBywrFOwIcwdUx?	MXu0PEBp	MYnEUXNQ	NV:1TYJPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh\2WwZTD3bZRpKEmFNUCgc4YhOTJwMEWg{txO	MnX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMUmxN\|AoRjJ{MUG5NVMxRC:jPh?=
A431	M{fPbWtqdmG\|ZTDBd5NigQ>?		NFnEdmgzKGh?	MVfEUXNQ	M4\VW2lvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iQUSzNUB4cXSqIFnDOVAhd2ZiMD6wNFEh\|ryP	NWHWTJV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNFEyOzJpPkKyNVAyOTN{PD;hQi=>
NCI-H292	NIr0VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGG0Oms4OiCq	MV7EUXNQ	MXjJR\|UxRTBwMEKg{txO	Mn;BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MU[0N\|MoRjJzOUG2OFM{RC:jPh?=
NCI-H1993	NHnYcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYj5d4xtPzJiaB?=	NGW0UFZFVVOR	NVPyRW8zUUN3ME2wMlEh\|ryP	M3vZS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUG2OFM{Lz5{MUmxOlQ{OzxxYU6=
Plasmodium falciparum					M3uxdZFJXFNicILv[oltcW6pIH\vdkBqdmirYnn0c5J{KG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBxem:uaX\ldoF1cW:w	NW\3Upg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVcxPDVpPkKxPFE4ODR3PD;hQi=>
MDA-MB-468	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\tNVAxKM7:TR?=	NIfDZ2I1QCCq	MlThSG1UVw>?	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eR?=	NGnpbpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUSyPVY{Oid-MkG0Nlk3OzJ:L3G+
PC3	M4XqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2noeVExKM7:TR?=	NFPNWlc4OiCq	MXXEUXNQ	MmTITWM2OD15LkSg{txO	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN3M{W0Okc,OjF\|NUO1OFY9N2F-
PC9	M3XS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXq[XFUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	M2qwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkC4PFAzLz5{MUKwPFgxOjxxYU6=
PC9	MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX2O3RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGVITlJvZHXmbYNq\W62IHj1cYFvKFCFOTDj[YxteyC5aYToJGVEPTBib3[gNE4xOTdizszN	M4n3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkC4PFAzLz5{MUKwPFgxOjxxYU6=
PANC1	M2foSGN6fG:2b4jpZ{BCe3OjeR?=		MUi1JIQ>	MlHCSG1UVw>?	M3\uZmlEPTB;NECuOFIh\|ryP	M4PUVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
MIAPaCa2	M1zCW2N6fG:2b4jpZ{BCe3OjeR?=		NHvMW3g2KGR?	MVjEUXNQ	M3fq[GlEPTB;NUCuOlIh\|ryP	NWTPfVdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
DU145	MXPDfZRwfG:6aXOgRZN{[Xl?		NGXTS5Y2KGR?	M{TYfGROW09?	MYPJR\|UxRTR{LkG3JO69VQ>?	NVnTNlhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
SMMC7721	MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUntSFJCPDhiaB?=		M{PrTWlEPTB;M{OuNVIh\|ryP	M2f0NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C0OVM4Lz5{MEOwOFU{PzxxYU6=
A375	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1\Od\|Q5KGh?		MkDxTWM2OD1{MD61OUDPxE1?	NHu4Woo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOwOFU{Pyd-MkCzNFQ2Ozd:L3G+
NCI-H1975	MULGeY5kfGmxbjDBd5NigQ>?	M2TvUVUh\|ryP	NFHhc2s1QCCq		MXfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGG\|c3Xzd4VlKGG\|IHHjeIl3[XSrb36gc4Yh[2G\|cHHz[U0{	NVO5[WRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOVE3PzBpPkKwNVUyPjdyPD;hQi=>
NCI-H1975	NXXjco52TnWwY4Tpc44hSXO\|YYm=	M2\XSFExKM7:TR?=			MVzJcohq[mm2aX;uJI9nKEWUQlKyJIF2fG:yaH;zdIhwenmuYYTpc44>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3MU[3NEc,OjBzNUG2O\|A9N2F-
NCI-H1975	M2XsZmtqdmG\|ZTDBd5NigQ>?	M1njRlExKM7:TR?=			MoLFTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44>	Mly0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUG2O\|AoRjJyMUWxOlcxRC:jPh?=
NCI-H1975	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnuW\|k2KM7:TR?=	M3PEOVczKGh?		NHvYRYtKSzVyPUiuNlYh\|ryP	NYKwcphKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOVE3PzBpPkKwNVUyPjdyPD;hQi=>
Sf9	NXrjeXFWU2mwYYPlJGF{e2G7		NVf5dlJqOTBibXnu	MYrEUXNQ	NXKyXGh6UW6qaXLpeIlwdiCxZjDFS2ZTKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKnY3XweI9zKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN\|IN88US=>	NH;CbIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC1OlQzPSd-MkCwOVY1OjV:L3G+
A431	NXnNWYdLU2mwYYPlJGF{e2G7	MVmxNFAh\|ryP	NX7aTnlzOTBibXnu		M2r3dXBzd2yxbnfl[EBqdmirYnn0c5J6KGGldHn2bZR6KG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9v	M3jNdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[5OFY2Lz5zOUm2PVQ3PTxxYU6=
A431	MWrLbY5ie2ViQYPzZZk>	NHXiWZYxNjFizszN	Mor3NUBp		MX3Jcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;u	NG\MVYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2PVQ3PSd-MUm5Olk1PjV:L3G+
A431	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\FTVExKM7:TR?=	M1H1dFczKGh?		NYnN[5FKT0l3ME2wMlUyPCEQvF2=	NVrSN2tTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5Olk1PjVpPkG5PVY6PDZ3PD;hQi=>
MCF7 MX	M{DnXmZ2dmO2aX;uJGF{e2G7		MmXHN\|AhdWmw		NXnW[m82UW6qaXLpeIlwdiCxZjDCR3JRKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4yKM7:TR?=	MknUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7M{K5OlAoRjF7OUOyPVYxRC:jPh?=
NIH3T3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIm3VIs4OiCq		MlH4S5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgUmlJNzOWMzDj[YxteyCneIDy[ZN{cW6pIHXyRlIh\2WwZTD3bZRpKEmFNUCgc4YhOC53NDFOwG0>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ4NUO3O{c,OTl4NkWzO\|c9N2F-
BA/F3	MmHmR5l1d3SxeHnjJGF{e2G7		NUfB[3VGPzJiaB?=		NHe0SY5EgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62IIfpeIghUUN3MDDv[kAxNjBzMEig{txO	NEnaU4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzPVIzQSd-MUmyN\|kzOjl:L3G+
HN5	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3G4RlczKGh?		NXrkT2h4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkB4cXSqIFXDOVAhd2ZiMD6wNUDPxE1?	M{jTblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEK4OFI1Lz5zOUCyPFQzPDxxYU6=
BT474	NHXDNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYq1WHFGPzJiaB?=		M4P6[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS0O\|Qh[2WubIOgc5ZmemW6cILld5NqdmdiRWLCZlIhf2m2aDDFR\|UxKG:oIECuN{DPxE1?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB{OESyOEc,OTlyMki0NlQ9N2F-
MCF7	MYDDfZRwfG:6aXOgRZN{[Xl?	MXm1NEDPxE1?	NWfuWJhDPzJiaB?=		MnrXTWM2OD1zMj6wOUDPxE1?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd5MUixPUc,OTh5N{G4NVk9N2F-
MOLT4	NYr4bJZNS3m2b4TvfIlkKEG\|c3H5		NEfzXmg6PiCq	NFqyXJlFVVOR	NXXtblIxUUN3ME2xOU4xOiEQvF2=	MnHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MUO4NFcoRjF6M{GzPFA4RC:jPh?=
MDA-MB-231	NXX6OphJS3m2b4TvfIlkKEG\|c3H5		M2rZV\|k3KGh?	MmP4SG1UVw>?	NGHNWI9KSzVyPUO2MlYyKM7:TR?=	MmH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MUO4NFcoRjF6M{GzPFA4RC:jPh?=
K562	M2HBTmN6fG:2b4jpZ{BCe3OjeR?=		M2TISFk3KGh?	MWnEUXNQ	NFrMe25KSzVyPUmuN\|Yh\|ryP	NX3JUXNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNVM5ODdpPkG4N\|E{QDB5PD;hQi=>
A549	MV;DfZRwfG:6aXOgRZN{[Xl?		Ml\xPVYhcA>?	MXjEUXNQ	NUH6[5FoUUN3ME2xN{42QSEQvF2=	NIrjbnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN\|gxPyd-MUizNVM5ODd:L3G+
COS7	M3vwNGZ2dmO2aX;uJGF{e2G7	NYe2clBjQTZizszN			MnKxTY5pcWKrdHnvckBw\iCqdX3hckBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPz[YQ>	M2Dx[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUe4O\|IzLz5zN{G3PFczOjxxYU6=
NIH3T3	M{fK[mZ2dmO2aX;uJGF{e2G7	M3vEWlAvOiEQvF2=	NYC4e3ZSOiCq	M4PIV2ROW09?	MkjkTY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txO	M1PvR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEiwNlg1Lz5zNkS4NFI5PDxxYU6=
KB	M4LGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjXSnk{UUN3ME2wMlA2PCEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjVzNkS3N{c,OTZ3MU[0O\|M9N2F-
GAK	NVrzfmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGX0UoNKSzVyPUKxMlQ6QSEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd7NUe2O{c,Ojl5OUW3Olc9N2F-
SK-N-AS	M3HlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3zcVhEUUN3ME2yNU42PjF7IN88US=>	NXjOOYIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2PVE{PDlpPkG5OlkyOzR7PD;hQi=>
OE33	NVT0O2l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvORm1sUUN3ME2yNU43ODR4IN88US=>	Mn73QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
YKG-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;Xd2lKSzVyPUKxMlY2PDVizszN	Mmi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NESxNVkoRjJ{OUS0NVE6RC:jPh?=
CAL-85	M4Xaemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nCdmlEPTB;MkGuPVMxPSEQvF2=	Mn3GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GzOVkoRjJ2NkOxN\|U6RC:jPh?=
NCI-H2347	NIK5TlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJzLkm0Nlgh\|ryP	NECyRmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKyNVc6OCd-MkiyNlE4QTB:L3G+
PANC-08-13	NV70PFA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknvTWM2OD1{Mj6wNVE6KM7:TR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{MUe5NEc,Ojh{MkG3PVA9N2F-
SK-N-FI	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mne5TWM2OD1{Mj6zNFc1KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
NEC8	NGTsWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[zTWM2OD1{Mj61NFc5KM7:TR?=	NXjUTnI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OFQyOTlpPkKyPVQ1OTF7PD;hQi=>
AN3-CA	NHTBS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\rR2RnUUN3ME2yNk43ODh2IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl2NEGxPUc,OjJ7NESxNVk9N2F-
HuO9	NFTrcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3:5TmlEPTB;MkKuO\|M6PiEQvF2=	M37l[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEOyN\|MyLz5{N{CzNlM{OTxxYU6=
COLO-800	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJ{Lke2OVMh\|ryP	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN2MUO1Okc,OjR\|NEGzOVY9N2F-
HT-29	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\5SmlEPTB;MkKuPFgzOyEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
OC-314	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\lTWM2OD1{Mj64PFQ2KM7:TR?=	NGSyTlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3N\|c1OCd-MkC4O\|M4PDB:L3G+
G-401	M{j0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJ\|LkC0OlIh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
Saos-2	NXPjW5ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP4TWM2OD1{Mz61NVgzKM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUm5PEc,OjR2N{G5PVg9N2F-
UACC-62	NUWxV5htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\JTotKSzVyPUKzMlU5OzNizszN	NUO3dHdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2PVE{PDlpPkG5OlkyOzR7PD;hQi=>
D-247MG	NH75[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vY[GlEPTB;MkOuO\|k{QSEQvF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
COLO-741	NWjkc3VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTEVHlyUUN3ME2yN{46PTZ3IN88US=>	MlW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3OEC1OVQoRjJyNUiwOVU1RC:jPh?=
ES3	NEC1U\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjuSXFKSzVyPUK0MlAxOjNizszN	Mkn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkG3PVAoRjJ6MkKxO\|kxRC:jPh?=
LNCaP-Clone-FGC	NFzBc\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfIb45KSzVyPUK0MlAzOTFizszN	Mm[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkG3PVAoRjJ6MkKxO\|kxRC:jPh?=
SW1710	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH20fZdKSzVyPUK0MlE2ODZizszN	M1XPOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEm0PVkzLz5{M{C5OFk6OjxxYU6=
LU-99A	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{n2R2lEPTB;MkSuNVg1OSEQvF2=	NWGzW3JmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NFI1PjRpPkG3OlAzPDZ2PD;hQi=>
HOP-92	M3H3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHjTWM2OD1{ND63NlUh\|ryP	MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G5PVgoRjJ2NEexPVk5RC:jPh?=
LS-123	M4r0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTJ2Lkm2NVQh\|ryP	NV62Z3NERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOFIyPDZpPkKyN\|QzOTR4PD;hQi=>
T84	M3;jcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi0SmFKSzVyPUK0Mlk4PjVizszN	MnfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|Mki2OVYoRjJ7M{K4OlU3RC:jPh?=
HCT-116	NEe4PHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4K4VGlEPTB;MkWuOFE5PiEQvF2=	MoPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2N{GxNVkoRjJ7NEexNVE6RC:jPh?=
M14	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTJ3LkS0OFch\|ryP	MnfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4MEK0OlQoRjF5NkCyOFY1RC:jPh?=
OCUB-M	NIPIdIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTJ3LkS0OVYh\|ryP	NIHGT4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
MKN45	NUnxXW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJ3Lk[zNVUh\|ryP	NEXoTmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyOVg4PSd-Mk[wNlU5PzV:L3G+
LCLC-97TM1	NInwdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrqSGJPUUN3ME2yOU44Ojh3IN88US=>	M1XNeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUi4NlgyLz5zOEW4PFI5OTxxYU6=
RVH-421	NUn6RWR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILCcHJKSzVyPUK1MlgyPjFizszN	MlL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{O3OFAoRjJyOEezO\|QxRC:jPh?=
NKS-81-FD	NU[4XXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTJ3LkmwNlEh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{MUe5NEc,Ojh{MkG3PVA9N2F-
NCI-H596	M1fRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJ4LkC0PFch\|ryP	NIPoeJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewN\|I6Pid-MkW3NFMzQTZ:L3G+
GB-1	NIPlOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIX5cphKSzVyPUK2MlE5PzlizszN	M1u5Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCyOFY1Lz5zN{[wNlQ3PDxxYU6=
ZR-75-30	NVGyTG0{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1L5bmlEPTB;Mk[uNlI6PyEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMkS2OEc,OTd4MEK0OlQ9N2F-
U-2-OS	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTJ4LkO3OVch\|ryP	NXLFcZJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOFIyPDZpPkKyN\|QzOTR4PD;hQi=>
HuP-T3	M1LqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnLTmZJUUN3ME2yOk43OTB{IN88US=>	NXjuNGZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO\|EyODV2PD;hQi=>
MOLT-16	M2q1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnCOFhvUUN3ME2yOk43OTZ4IN88US=>	NIf5OZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wNlQ3PCd-MUe2NFI1PjR:L3G+
U-87-MG	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnyenhKSzVyPUK2Mlc1OzhizszN	M3v2XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{[yOFc1Lz5zOUO2NlQ4PDxxYU6=
8505C	M{TtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjlfolOUUN3ME2yOk46OTJ4IN88US=>	NUHtdGJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PFgzQDFpPkG4OVg5OjhzPD;hQi=>
SK-MEL-3	M1HEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTJ4Lkm4Nlgh\|ryP	MmO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NEKxOFYoRjJ{M{SyNVQ3RC:jPh?=
COLO-824	M{TwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnicYJKSzVyPUK3MlIyQTVizszN	NFznUpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVM2QSd-MkS2N\|E{PTl:L3G+
EW-1	NV7xOXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYflWpFUUUN3ME2yO{4{PTV2IN88US=>	NX;aVJltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OVYzODJpPkK5OlU3OjB{PD;hQi=>
UACC-257	NUnEOIh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTJ5LkO4NFQh\|ryP	NF74Xpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKyNVc6OCd-MkiyNlE4QTB:L3G+
Hs-578-T	NWnyUZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWf6SW9KUUN3ME2yO{42Ojl7IN88US=>	NUG0WnF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|E{PTlpPkK0OlMyOzV7PD;hQi=>
UACC-893	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4[xVWlEPTB;MkeuOlY{OSEQvF2=	M4SwXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{SyNVQ3Lz5{MkO0NlE1PjxxYU6=
MHH-NB-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvDTWM2OD1{Nz64NFA4KM7:TR?=	MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{O3OFAoRjJyOEezO\|QxRC:jPh?=
KYSE-410	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWC5eGNMUUN3ME2yPE4zPzd7IN88US=>	M2TNZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
SF126	M{PQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojkTWM2OD1{OD63OFM2KM7:TR?=	M2f0[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
HT-144	NXvZRm9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HkfWlEPTB;MkmuN\|M3OiEQvF2=	MmnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NEKxOFYoRjJ{M{SyNVQ3RC:jPh?=
SW1573	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJ7LkO1NFkh\|ryP	MnLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkW4O\|UoRjJ4MEK1PFc2RC:jPh?=
SW620	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTJ7LkO2OFEh\|ryP	Mn6xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyN{W1PVIoRjJ6MEe1OVkzRC:jPh?=
SCH	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Kw[WlEPTB;MkmuPFg{OSEQvF2=	MonVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{O3OFAoRjJyOEezO\|QxRC:jPh?=
EW-22	M4TaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDiO3JvUUN3ME2zNE4yQTZ7IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyM{K5Okc,OjV5MEOyPVY9N2F-
H4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonVTWM2OD1\|MD60OlU1KM7:TR?=	NX\ZOFRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlU5PzVpPkK2NFI2QDd3PD;hQi=>
CAS-1	NFfqUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTNyLke4OVkh\|ryP	NUX2fVM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E6QThpPkK0OFcyQTl6PD;hQi=>
MG-63	NH3XN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjpOWh7UUN3ME2zNE45PDd6IN88US=>	NH7JWoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
MDA-MB-415	M4fIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrOVIlKSzVyPUOxMlE4PTNizszN	NVy1cXpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
NCI-H1395	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTNzLkKzNlgh\|ryP	NETxVHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO2NlQ4PCd-MUmzOlI1PzR:L3G+
Ca-Ski	NWSzVWJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDxTWM2OD1\|MT6zNVc4KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
BxPC-3	NX;3XIF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXneGFKSzVyPUOxMlM4OjlizszN	NF23SoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVM2QSd-MkS2N\|E{PTl:L3G+
A3-KAW	NEDMbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGK2XFZKSzVyPUOxMlQ1PzFizszN	MluzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4MEK0OlQoRjF5NkCyOFY1RC:jPh?=
T-24	NXLobIxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITsOJpKSzVyPUOxMlc{PjJizszN	NVnVXVlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1PFA2PTRpPkKwOVgxPTV2PD;hQi=>
NCI-H2029	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTNzLke3OlUh\|ryP	MkjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G5PVgoRjJ2NEexPVk5RC:jPh?=
YAPC	NEPNfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTN{LkC0NFch\|ryP	MoTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
SK-MEL-2	NUfHS2l1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PUNGlEPTB;M{KuNFUzKM7:TR?=	NF7Fe\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO2NlQ4PCd-MUmzOlI1PzR:L3G+
LS-513	NYWyd29ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTN{LkGxPFch\|ryP	MkHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
AsPC-1	NEnHSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrhTWM2OD1\|Mj6zOlA2KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzFyMU[3OEc,OTdzMEG2O\|Q9N2F-
KYSE-150	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPzV2o{UUN3ME2zNk4{Pzd\|IN88US=>	M3W0O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkOwNVMyLz5{M{KzNFE{OTxxYU6=
NCI-H520	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvGTWM2OD1\|Mj60OFgzKM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
JEG-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XX[mlEPTB;M{OuNFk4OSEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|MEGzNUc,OjN{M{CxN\|E9N2F-
GMS-10	M2TNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGniflFKSzVyPUOzMlMxODRizszN	Mn;iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
HT-1080	M{e4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7kXVhKSzVyPUOzMlM6KM7:TR?=	NWnVSoc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPVU1PjZpPkK0NVk2PDZ4PD;hQi=>
NCI-H1651	MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rVUmlEPTB;M{OuN\|k3KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTN4MkS3OEc,OTl\|NkK0O\|Q9N2F-
NCI-H2122	MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkm4TWM2OD1\|Mz61OVc1KM7:TR?=	NYjxem9URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|M4PDBpPkKwPFc{PzRyPD;hQi=>
ES5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\yWYxGUUN3ME2zN{44Ojl{IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ3NkKwNkc,Ojl4NU[yNFI9N2F-
8305C	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXJN5BxUUN3ME2zN{46QTN5IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTN4MkS3OEc,OTl\|NkK0O\|Q9N2F-
KM12	NEHvOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITUXGhKSzVyPUO0MlA1PzhizszN	NIDzeHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzNFE{OSd-MkOyN\|AyOzF:L3G+
HCT-15	NEjUc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rXNGlEPTB;M{SuNVI4KM7:TR?=	NYO0O3k3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5Olg5OjRpPkKzPVY5QDJ2PD;hQi=>
OVCAR-5	M{[3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTJTWM2OD1\|ND6yNVgzKM7:TR?=	MlziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nke1PVAoRjJ2OE[3OVkxRC:jPh?=
NCI-H2291	NXvJ[llnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DhO2lEPTB;M{SuNlQ4OiEQvF2=	M1jP[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkOwNVMyLz5{M{KzNFE{OTxxYU6=
CP50-MEL-B	NFfsVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1uyVGlEPTB;M{SuOlU6OiEQvF2=	Ml\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEW3NlIoRjJ3MUC1O\|IzRC:jPh?=
C-33-A	M4HKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XyU2lEPTB;M{SuOlg2PyEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl4Nkm1NEc,Ojd7Nk[5OVA9N2F-
NCI-H2452	M3H6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGSzN3VKSzVyPUO0Mlc5QDJizszN	MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
MDA-MB-157	M3jlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjzTWM2OD1\|ND64NVk{KM7:TR?=	NWThT5duRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOlI1PzRpPkG5N\|YzPDd2PD;hQi=>
LN-405	M3nET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrzTo9KSzVyPUO1MlQ{ODhizszN	M{K0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEezO\|QxLz5{MEi3N\|c1ODxxYU6=
MDA-MB-231	M1TyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTSTWM2OD1\|NT61NFU1KM7:TR?=	M3fVOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{[wNVA1Lz5{M{O2NFExPDxxYU6=
EW-24	Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fy[2lEPTB;M{WuOlM{PSEQvF2=	M3zVNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[4PFI1Lz5{M{m2PFgzPDxxYU6=
MKN28	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknsTWM2OD1\|NT64NlM3KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTN4MkS3OEc,OTl\|NkK0O\|Q9N2F-
KINGS-1	NEjINI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;VUIlKSzVyPUO1Mlg1OzRizszN	NFXOeVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOyPFY2Pid-MkmzNlg3PTZ:L3G+
LC-2-ad	NEjnUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjBOGxKSzVyPUO2MlY6QSEQvF2=	M{D0NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNlk3Lz5{NUewN\|I6PjxxYU6=
IGR-1	NV\0XlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33Y[GlEPTB;M{[uO\|A4PSEQvF2=	M{LzflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEO2PVk1Lz5{NESzOlk6PDxxYU6=
SW626	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXixXJE1UUN3ME2zO{4xPDF5IN88US=>	M1vlR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUGyPVA5Lz5{MkWxNlkxQDxxYU6=
ONS-76	NITETFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjtTWM2OD1\|Nz6xN\|A6KM7:TR?=	MkG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nki4NlQoRjJ\|OU[4PFI1RC:jPh?=
T98G	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\EUmdFUUN3ME2zO{45PjN3IN88US=>	NGXiTGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
NB14	NUHMd4p6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fUemlEPTB;M{iuOFU1PCEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|Nkm5OEc,OjR2M{[5PVQ9N2F-
D-423MG	M2n2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTN6LkS4Olkh\|ryP	Mmj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
NCI-H510A	NIfGPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\PUW1jUUN3ME2zPE43PDVzIN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR7NUC4NUc,Ojh2OUWwPFE9N2F-
NMC-G1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmG5TWM2OD1\|OD63NlIzKM7:TR?=	NXPPUpNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO\|EyODV2PD;hQi=>
SW948	NIf5bVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;1T3hyUUN3ME2zPE45QTR7IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN2MUO1Okc,OjR\|NEGzOVY9N2F-
MFM-223	NXL3ZopUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17oOGlEPTB;M{iuPVQ{OSEQvF2=	M3f5SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG5OlA1Lz5zN{SxPVYxPDxxYU6=
PAN1	M4XYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvOTWM2OD1\|OD65PVE6KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjVzMkmwPEc,OjJ3MUK5NFg9N2F-
MZ7-mel	NH76fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXpTWM2OD1\|OT6xNVk6KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB5NUW5Nkc,OjhyN{W1PVI9N2F-
COLO-679	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTN7Lkm3NFgh\|ryP	Mln0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
SW872	NGfT[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTRyLkKwN\|Eh\|ryP	NYnTfWlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|E{PTlpPkK0OlMyOzV7PD;hQi=>
HT-1197	Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTRyLkK4Olkh\|ryP	M3viW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{S5N\|MzLz5{N{O0PVM{OjxxYU6=
ES6	NV;QRZBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHyR3FKSzVyPUSwMlQ2PTJizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDF6Nk[wOEc,OThzOE[2NFQ9N2F-
SNU-387	NGm4[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DJS2lEPTB;NECuPFI{QCEQvF2=	NH72O289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxPVYxPCd-MUe0NVk3ODR:L3G+
T47D	M1HLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nwbWlEPTB;NEGuNFE6OiEQvF2=	NGP1Z3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEG4OlYxPCd-MUixPFY3ODR:L3G+
G-402	NUXrenhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEf5W25KSzVyPUSxMlA5ODlizszN	NIO0ZmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S4PVYzPid-MkO0PFk3OjZ:L3G+
MZ1-PC	NF;yS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTRzLkixJO69VQ>?	MkjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4MEK0OlQoRjF5NkCyOFY1RC:jPh?=
SW1417	M3j3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rvWGlEPTB;NEKuN\|A{KM7:TR?=	NFH3VZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wNlQ3PCd-MUe2NFI1PjR:L3G+
RERF-LC-MS	NEDxOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTR{LkWwPFch\|ryP	NHnmVoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW3OlY{Oyd-Mki1O\|Y3OzN:L3G+
SF539	M4\rSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTR{LkW1Nlkh\|ryP	M{TRR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5OlI3Lz5{M{S4PVYzPjxxYU6=
ESS-1	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnpTok6UUN3ME20N{42PTV6IN88US=>	MmL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3N{[2N\|MoRjJ6NUe2OlM{RC:jPh?=
RO82-W-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlS1TWM2OD12Mz62NVU{KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV5Nk[zN{c,Ojh3N{[2N\|M9N2F-
S-117	NF[xOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkC5TWM2OD12Mz62PVU5KM7:TR?=	M2HkS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUGyPVA5Lz5{MkWxNlkxQDxxYU6=
SW756	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTR\|LkiyOFIh\|ryP	M1TLVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CP66-MEL	NU\CXHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTR3LkexOFMh\|ryP	NHPLPWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
H-EMC-SS	NXXHdVZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEO3e3pKSzVyPUS1Mlc3QTNizszN	NFrve\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H2052	NVLvOJlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjYc\|lKSzVyPUS1MlkxOjdizszN	M1rt[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SW684	NIHZWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nZO2lEPTB;NEeuNFA5OSEQvF2=	NXLucI1[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCC1569	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnGTWM2OD12Nz6xOlU5KM7:TR?=	NIfu[lE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KGN	NH7YPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrrVWdiUUN3ME20O{4{OzFzIN88US=>	NIfPPYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LCLC-103H	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rHVWlEPTB;NEeuOFQxPCEQvF2=	NV;lUI9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SW780	M{\IdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTR5Lk[zOVEh\|ryP	NWPkO3cyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1703	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILnRpRKSzVyPUS4MlM{PTJizszN	NFXTT5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC1395	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHWZnlQUUN3ME20PE44PDN{IN88US=>	NGnuSIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method:
Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

(Only for Reference)

Animal Research:

^[3]

- Collapse

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Water	Insoluble
	Ethanol	'4 mg/mL warmed
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Iressa
Smiles	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Active not recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804100	Unknown status	--	Carcinoma Non-Small-Cell Lung\|Bronchial Neoplasms\|Carcinoma Bronchogenic\|Lung Diseases\|Lung Neoplasms	Wenzhou Medical University	May 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)